Mineralocorticoid Receptor Antagonist

Finerenone Efficacy in Cardio-Kidney-Metabolic Syndrome Patients With or Without History of Cancer: Insights from the FINE-HEART Analysis

By MedXY 08/19/2026

Finerenone reduces mortality, cardiovascular, and kidney complications in cardio-kidney-metabolic syndrome patients regardless of cancer history, while patients with cancer experience greater disease burden and adverse events.

Cardiology Nephrology news

Finerenone May Lower Sudden Death Risk Across the Cardio-Kidney-Metabolic Continuum

By MedXY 06/09/2026

A prespecified pooled analysis of 18,991 participants found finerenone was associated with a significant reduction in sudden death across chronic kidney disease, type 2 diabetes, and heart failure populations.

Cardiology Clinical Updates news

Finerenone in the Management of HFmrEF and HFpEF: A Comprehensive Synthesis of Evidence from the FINEARTS-HF Trial

By MedXY 12/26/2025

This clinical review synthesizes data from the FINEARTS-HF trial, highlighting finerenone's efficacy in reducing heart failure events and cardiovascular mortality across diverse patient profiles, including those with frailty, obesity, and chronic obstructive pulmonary disease.

Cardiology news Specialties

Diuretic-Sparing Potential of Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: Insights from FINEARTS-HF

By MedXY 08/19/2025

Finerenone consistently reduces heart failure events and allows reduction of loop diuretic dosages without impacting new loop diuretic initiation, demonstrating a diuretic-sparing effect in HFmrEF/HFpEF patients.